Thus, rodent data support that the chemical chaperones might be reprofiled to treat metabolic syndrome and it is tempting to speculate that targeting hypothalamic ER stress, and more specifically GRP78, may be a suitable strategy for the treatment of obesity and associated comorbidities. This evidence concerns the gene HSPA5 and metabolic syndrome.